Skip to content

ACULAR LS® (ketorolac tromethamine ophthalmic solution) 0.4%

ACULAR LS

ACULAR LS® is the number-one prescribed non-steroidal anti-inflammatory (NSAID) by U.S. ophthalmologists1 and is indicated to reduce pain, burning and stinging following corneal refractive surgery. Approved by the U.S. Food and Drug Administration in 2003, the optimized 0.4 percent formulation of ACULAR LS® is clinically proven to block the source of post-corneal refractive surgical eye pain. ACULAR LS® has been shown to achieve significant and rapid pain relief.2

Important Safety Information

There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory agents. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.

With some NSAIDs there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.

Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.

It is recommended that ACULAR LS® ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications, which may prolong bleeding time.

The most frequently reported adverse reactions occurring in approximately 1 to 5 percent of the study population were eye redness, corneal infiltrates, headache, ocular edema and ocular pain.

Please See Full ACULAR LS® Product Information (PDF) 

Allergan External Disease Portfolio Fact Sheet (PDF) 



  1. Vector One: National (VONA) from Verispan; March 2007.
  2. Solomon K, Donnenfeld E, Raizman M, et al. Safety and efficacy of Ketorolac tromethamine .04% ophthalmic solution in post-photorefractive Keratectomy patients. J Cataract Refract Surg. 2004; 30:1653-1660.